Medicare's drug price negotiation is of concern to industry, says GlobalData

24 August 2022
globaldata

The passing of the $740 billion Inflation Reduction Act, which aims to control and lower prescription drug costs, will be welcome news for patients feeling the repercussions of rising inflation and a cost-of-living crunch in the USA. However, GlobalData predicts that few pharma companies will be left unaffected by its provisions, with its full effects only being felt until 2026.

The Act includes the previously announced Centers of Medicare & Medicaid Services (CMS) drug price negotiation provisions, which will allow Medicare the power to negotiate with and supersede the pharmaceutical industry over drug pricing. These negotiated prices will come into effect in 2026.

GlobalData forecasts that total US pharmaceutical sales of prescription and non-prescription drugs are set to reach $624 billion in 2023. There is also the plan to invest in extending the expanded Affordable Care Act (ACA) provisions for three years, through to 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical